群馬大学大学院病態腫瘍薬理学・がん治療臨床開発学

キーワードを入力してください

>サイトマップ

>日本語

業績

2016

原著論文

1. Kaira K, Toyoda M, Shimizu A, Imai H, Sakakura K, Nikkuni O, Suzuki M, Iijima M, Asao T, Chikamatsu K. Decreasing expression of Glucose-regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. Head Neck. 2016 in press.

2. Takahashi K, Kaira K, Shimizu A, Sat T, Tamahashi N, Ogawa H, Yoshinari D, Yokobori T, Asao T, Takeyoshi I, Oyama T. Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. Tumor Biology 2016 in press

3. Shimizu A, Kaira K, Yasuda M, Asao T, Ishikawa O. Decreased expression of class III β-tubulin is associated with unfavorable prognosis in patients with malignant melanoma: Melanoma Res 2016;26:29-34.

4. Honjo H, Kaira K, Miyazaki T, Yokobori T, Kanai Y, Nagamori S, Oyama T, Asao T, Kuwano H. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. J Surg Oncol 2015 in press.

5. Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Matsumoto S, Taira T, Kenmotsu H, Harada H, Naito T, Murakami H, Endo M, Nakajima T, Yamada M, Takahashi T. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer 2015 in press

6. Kaira K, Toyoda M, Shimizu A, Imai H, Sakura K, Nikkuni, Suzuki M, Iijima M, Asao T, Chikamatsu K. Prognostic significance of GRP78/BiP expression in patients with stage III/IV hypopharyngeal squamous cell carcinoma. Neoplasma 2016 in press.

7. Enokida Y, Shimizu K, Atsumi J, Kakegawa S, Takase Y, Kaira K, Yashima H, Nakazawa S, Ohtaki Y, Nagashima T, Lezhava A, Usui K, Ishikawa T, Hayashizaki Y, Takeyoshi I. Prognostic potent of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma. Cancer Med 2016 in press

8. Ohtaki Y, Shimizu K, Kaira K, Nagashima T, Obayashi K, Nakazawa S, Kakegawa S, Igai H, Kamiyoshihara M, Nishiyama M, Takeyoshi I. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer. Surg Today. 2016 Jan 19. [Epub ahead of print]

9. Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Oriuchi N, Nagamori S, Kanai Y. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging. Cancer Sci 2016 in press.

10. Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Kato Y, Oriuchi N, Nagamori S, Kanai Y. Transport of 3-fluoro-l-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [18F]FAMT positron emission tomography. J Pharmacol Sci. 2016 in press.

11. Kimura A, Ogata K, Altan B, Yokobori T, Ide M, Mochiki E, Toyomasu Y, Kogure N, Yanoma T, Suzuki M, Bai T, Oyama T, Kuwano H.Oncotarget. Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer. 2016 Mar 1.

12. Tsukagoshi M, Wada S, Yokobori T, Altan B, Ishii N, Watanabe A, Kubo N, Saito F, Araki K, Suzuki H, Hosouchi Y, Kuwano H. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Cancer Sci. 2016 Feb;107(2):116-22.

13. Altan B, Yokobori T, Ide M, Mochiki E, Toyomasu Y, Kogure N, Kimura A, Hara K, Bai T, Bao P, Suzuki M, Ogata K, Asao T, Nishiyama M, Oyama T, Kuwano H. Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. Gastric Cancer. 2015 Oct 15.

14. Saito F, Araki K, Yokobori T, Ishii N, Tsukagoshi M, Watanabe A, Kubo N, Altan B, Shirabe K, Kuwano H. High expression of karyopherin-α2 and stathmin 1 is associated with proliferation potency and transformation in the bile duct and gall bladder epithelia in the cases of pancreaticobiliary maljunction. J Surg Oncol. 2016 Jun 23.

2015

総説論文

1. Sunaga N, Kaira K. Epiregulin as a therapeutic target in non-small-cell lung cancer. Lung Cancer:Targets and Therapy 2015;6:91-8.

原著論文

1. Shimizu A, Kaira K, Mori K, Kato M, Shimizu K, Yasuda M, Takahashi A, Oyama T, Asao T, Ishikawa O. Prognostic significance of β2-adrenergic receptor expression in malignant melanoma. Tumor Biology 2015 in press.

2. Shimizu A, Kaira K, Yasuda M, Asao T, Ishikawa O. Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma. Neoplasms 2015 in press.

3. Shimizu A, Kaira K, Yasuda M, Asao T, Ishikawa O. Decreased expression of class III β-tubulin is associated with unfavorable prognosis in patients with malignant melanoma. Melanoma Res 2015 in press.

4. Kaira K, Toyoda M, Shimizu A, Shino M, Sakakura K, Takayasu Y, Takahashi K, Asao T, Chikamatsu K. Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma. Acta Oto-laryngologica 2015 in press.

5. Kaira K, Sunaga N, Imai H, Kamide Y, koga Y, Ono A, Kuwako T, Masuda T, Hisada T Ishizuka T , Yamada M. Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. Int J Clin Oncol 2015 in press.

6. Yazawa T, Shimizu K, Kaira K, Nagashima T, Ohtaki Y, Atsumi J, Obayashi K, Nagamori S, Kanai Y, Oyama T, Takeyoshi I. Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. Am J Transl Res 2015 in press.

7. Kaira K, Nakamura K, Hirakawa T, Imai H, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Tsukamoto N, Oyama T, Asao T, Minegishi T. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. Am J Transl Res 2015 in press.

8. Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Asao T, Ishikawa O. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Res 2015;25:399-405.

9. Nikkuni O, Kaira K, Toyoda M, Shino M, Sakakura M, Takahashi K, Tominaga H, Oriuchi N, Suzuki M, Iijima M, Asao T, Nishiyama M, Nagamori S, Kanai Y, Oyama T, Chikamatsu K. Expression of amino acid transporters (LAT1 and ASCT2) in patients with stage III/IV laryngeal squamous cell carcinoma. Pathol Oncol Res 2015 in press.

10. Miura S, Kaira K, Kaira R, Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N. The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. Invest New Drugs. 2015 Apr 7. [Epub ahead of print]

11. Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T, Yoshino R, Kenmotsu H, Saitoh J, Harada H, Naito T, Murakami H, Tomizawa Y, Matsuura M, Saito R, Nakajima T, Yamada M, Takahashi T. Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. Springerplus. 2015 Mar 31;4:152

12. Kaira K, Arakawa K, Shimizu K, Oriuchi N, Nagamori S, Kanai, Oyama T, Takeyoshi I. Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. Am J Transl Res 2015;7:356-63.

13. Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Takeyoshi I. Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. Histopathology. 2015 Jan;66(2):234-43.

14. Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol. 2015 Oct;76(4):761-9.

15. Yoshino R, Imai H, Mori K, Tomizawa Y, Takei K, Tomizawa M, Kaira K, Yoshii A, Watanabe S, Saito R, Yamada M. Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer. J Cancer Res Ther. 2015 Jul-Sep;11(3):606-11.

16. Kasahara N, Imai H, Kaira K, Mori K, Wakuda K, Ono A, Taira T, Kenmotsu H, Harada H, Naito T, Murakami H, Endo M, Nakajima T, Yamada M, Takahashi T. Clinical impact of post-proression survival on overall in patients with limited-line chemoradiotherapy. Radiol Oncology

17. Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato Km Takise A, Saito R, Yamada M: Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring EGFR mutations. Clin Transl Oncol 2015 in press.

18. Kato M, Shimizu A, Yokoyama Y, Kaira K, Shimomura Y, Ishida-Yamamoto A, Kamei K, Tokunaga F, Ishikawa O. An Autosomal Recessive Mutation of DSG4 Causes Monilethrix through the ER Stress Response. J Invest Dermatol. 2015 Jan 23. [Epub ahead of print]

19. Sakakura K, Takahashi H, Kaira K, Toyoda M, Oyama T, Chikamatsu K. Immunological significance of the accumulation of autophagy components in oral squamous cell carcinoma. Cancer Sci. 2015 Jan;106(1):1-8.

20. Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Yamamoto N, Takahashi T. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med 2015 Jan-Mar;10(1):61-6.

21. Imai H, Murakami H, Yoshino R, Mori K, Sumita K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Harada H, Naito T, Kaira K, Tomizawa Y, Ohde Y, Matsuura M, Endo M, Saito R, Nakajima T, Takahashi T: Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients . J BUON 2015 in press

22. Yokobori Y, Toyoda M, Sakura K, Kaira K, Tsushima Y, Chikamatsu K. 18F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. Acta Oto-laryngologica 2015 Mar 5:1-6. [Epub ahead of print]

23. Yokobori T, Bao P, Fukuchi M, Altan B, Ozawa D, Rokudai S, Bai T, Kumakura Y, Honjo H, Hara K, Sakai M, Sohda M, Miyazaki T, Ide M, Nishiyama M, Oyama T, Kuwano H. Nuclear PROX1 is Associated with Hypoxia-Inducible Factor 1α Expression and Cancer Progression in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1566-73.

24. Azuma Y, Yokobori T, Mogi A, Altan B, Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M, Kuwano H. SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J Surg Oncol. 2015 Aug;112(2):231-7.

25. Kuranami S, Yokobori T, Mogi A, Altan B, Yajima T, Onozato R, Azuma Y, Iijima M, Kosaka T, Kuwano H. Src kinase-associated phosphoprotein2 expression is associated with poor prognosis in non-small cell lung cancer. Anticancer Res. 2015 Apr;35(4):2411-5.

26. Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T, Kuwano H. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015 Mar;36(3):338-45.

症例報告

1. Shimizu A, Hattori M, Kaira K, Ishikawa O. Keratotic condyloma acuminatum. J Dermatol 2015 in press

2. Chino H, Hagiwara E, Sugisaki M, Baba T, Koga Y, Hisada T, Kaira K, Okudela K, Takemura T, Dobashi K, Ogura T. Pulmonary Aluminosis Diagnosed with In-air Microparticle Induced X-ray Emission Analysis of Particles. Intern Med. 2015;54(16):2035-40

3. Kaira K, Naruse I, Imai H, Sunaga N, Hisada T, Motegi M, Asao T, Yamada M. Dramatic response of S-1 administration to chemorefractory advanced thymic cancer. Chemotehrapy 2015 in press.

4. Kaira K, Imai H, Yamada M. Recurrent intimal sarcoma mimicking pulmonary embolism. Jpn J Clin Oncol. 2015 Apr 23.

5. Kamide Y, Kaira K, Hisada T, et al. ALK rearrangement positive lung cancer with transformation to pleomorphic carcinoma. Internal Med 2015 in press.

2014

原著論文

1. Namikawa M, Kakizaki S, Kaira K, Tojima H, Yamazaki Y, Horiguchi N, Sato K, Oriuchi N, Tominaga H, Sunose Y, Nagamori S, Kanai Y, Oyama T, Takeyoshi I, Yamada M. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res. 2014 Oct 9.

2. Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M, Sawamura M. Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci. 2014 Nov;105(11):1496-502. 

3. Toyoda M, Kaira K, Shino M, Sakakura K, Takahashi K, Takayasu Y, Tominaga H, Oriuchi N, Nikkuni O, Suzuki M, Iijima M, Tsukamoto N, Nagamori S, Kanai Y, Oyama T, Chikamatsu K. CD98 is a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma. Head Neck. 2014 Jun 10. [Epub ahead of print].

4. Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, Takayasu Y, Takahashi K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Chikamatsu K. Prognostic significance of Amino Acid Transporter Expression (LAT1, ASCT2 and xCT) in Surgically Resected Tongue Cancer. Br J Cancer. 2014 Mar 13;110(10):2506-13. 

5. Suzuki S, Kaira K, Ohshima Y, Ishioka NS, Sohda M, Yokobori T, Miyazaki T, Oriuchi N, Tominaga H, Kanai Y, Tsukamoto N, Asao T, Tsushima Y, Higuchi T, Oyama T, Kuwano H. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer. 2014 Apr 15;110(8):1985-91. 

6. Kaira K, Sunose Y, Oriuchi N, Kanai Y, Takeyoshi I. CD98 as a promising biomarker of prognosis in biliary tract cancer. Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):654-7.

7. Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M, Oyama T, Takeyoshi I. ASC amino acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer 2014 Apr 15;110(8):2030-9. 

8. Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y,Nagashima T, Kasahara N, Kawashima O, Hisada T, R Saito, Yamada M. Clinicopathological and prognostic significance of interleukin-8 expression andits relationship to KRAS mutation in lung adenocarcinoma. Br J Cancer 2014 Apr 15;110(8):2047-53.

9. Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T, Yamamoto N. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 2014 Feb;83(2):197-204.

10. Kaira K, Yamamoto N, Endo M, Kenmotsu H, Naito T, Ono A, Murakami H, Ohde Y, Nakajima T, Takahashi T. 18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. Oncol Rep. 2014 Jan;31(1):209-15.

11. Kaira K, Yamamoto N, Kenmotsu H, Murakami H, Ono A, Naito T, Endo M, Takahashi T. Prognostic impact of F-FDG uptake on PET in non0small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy. Respir Investig. 2014 Mar;52(2):121-8.

12. Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, Hisamatsu Y, Tokito T, Imai H, Akamatsu H, Ono A, Kaira K, Murakami H, Endo M, Mori K, Takahashi T, Yamamoto N. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2014 Nov 29. [Epub ahead of print]

13. Shimizu A, Kato M, Takeuchi Y, Sano T, Kaira K, Uezato H, Ishikawa O. Detection of human papillomavirus (HPV) in patients with squamous cell carcinoma and the clinical characteristics of HPV-positive cases. Br J Dermatol. 2014 Oct;171(4):779-85.

14. Yoshino R, Imai H, Mori K, Takei K, Tomizawa M, Kaira K, Yoshii A, Tomizawa Y, Saito R, Yamada M. Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Mol Clin Oncol. 2014 Sep;2(5):731-736.

15. Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, Nagashima T, Ohtaki Y, Kaira K, Sunaga N, Yanagitani N, Yoshino R, Tsunekawa K, Igai H, Kamiyoshihara M, Usui K, Lezhava A, Tomizawa Y, Ishikawa T, Murakami M, Hayashizaki Y, Takeyoshi I. Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk. Biomed Rep. 2014 Sep;2(5):719-724.

16. Kotake M, Sato K, Mogi C, Tobo M, Aoki H, Ishizuka T, Sunaga N, Imai H, Kaira K, Hisada T, Yamada M, Okajima F. Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca2+/neuronal NOS pathway in N1E-115 neuronal cells. Cell Signal. 2014 Nov;26(11):2326-32.

17. Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M. Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma. Inflamm Res. 2014 Sep;63(9):789-96.

18. Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Takahashi T. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Med Oncol. 2014 Aug;31(8):88.

19. Ohtaki Y, Shimizu K, Kakegawa S, Nagashima T, Nakano T, Atsumi J, Enokida Y, Igai H, Ibe T, Sugano M, Kamiyoshihara M, Kawashima O, Kaira K, Sunaga N, Takeyoshi I. Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status. Mol Clin Oncol. 2014 Mar;2(2):187-196.

20. Watanabe A, Suzuki H, Yokobori T, Tsukagoshi M, Altan B, Kubo N, Suzuki S, Araki K, Wada S, Kashiwabara K, Hosouchi Y, Kuwano H. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014 Jun;105(6):690-6.

21. Yazawa S, Yokobori T, Ueta G, Ide M, Altan B, Thongprachum A, Nishimura T, Nakajima T, Kominato Y, Asao T, Saniabadi AR, Furukawa K, Kuwano H, Le Pendu J, Ushijima H. Blood group substances as potential therapeutic agents for the prevention and treatment of infection with noroviruses proving novel binding patterns in human tissues. PLoS One. 2014 Feb 18;9(2):e89071.

22. Yokobori T, Yokoyama Y, Mogi A, Endoh H, Altan B, Kosaka T, Yamaki E, Yajima T, Tomizawa K, Azuma Y, Onozato R, Miyazaki T, Tanaka S, Kuwano H. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Mol Cancer Res. 2014 Jan;12(1):32-7.

症例報告

1. Shimoda Y, Satoh T, Takahashi H, Katano-Toki A, Ozawa A, Tomaru T, Horiguchi N, Kaira K, Nishioka M, Shibusawa N, Hashimoto K, Wakino S, Mori M, Yamada M. A case of thyroid storm with a markedly elevated level of circulating soluble interleukin-2 receptor complicated by multiple organ failure and disseminated intravascular coagulation syndrome. Endocr J. 2014 Apr 20. [Epub ahead of print].

2. Watanabe T, Kaira K, Mizuide M, Sunaga N, Shibusawa N, Hisada H, Satoh T, Mori M, Yamada M. Solitary pituitary metastasis resulting from pulmonary large cell neuroendocrine carcinoma. World J Respirology 2014 in press.

3. Kaira K, Okamura T, Takahashi H, Horiguchi N, Sunaga N, Hisada T, Yamada M. Small cell lung cancer with VGCC antibody-positive paraneoplastic limbic encephalitis: a case report. J Med Case Rep 2014 Apr 8;8:119. 

2013

総説論文

1. Sunaga N, Kaira K, Hisada T, Yamada M. FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer. World J Respirol. 2013;3(3):104-109.

原著論文

1. Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Yamaguchi A, Segawa A, Ide M, Mori M, Oyama T, Takeyoshi I. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 2013 Oct 16;13(1):482.

2. Kaira R, Kaira K, Shukuya T, Kenmotsu H, Ono A, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N, Takahashi T. Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy. World J Respirology 2013 Nov;28 3(3):110-115.

3. Ayabe E, Kaira K, Harada H, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Nishimura T, Yamamoto N, Takahashi T. Prognosis of patients with brain metastasis from non-small cell lung cancer according to gefitinib administration. J Tumor 2013 Oct;18 1(5):20-23.

4. Kaira K, Murakami H, Endo M, Ohde Y, Naito T, Kondo H, Nakajima T, Yamamoto N, Takahashi T. Biological Correlation of 18F-FDG Uptake on PET in Pulmonary Neuroendocrine Tumors. Anticancer Res. 2013 Oct;33(10):4219-28.

5. Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh JI, Nakano T, Sunaga N. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer. 2013 Dec;82(3):449-54.

6. Nobusawa A, Kim A, Kaira K, Miyashita G, Negishi A, Oriuchi N, Higuchi T, Tsushima Y, Kanai Y, Yokoo S, Oyama T. Diagnostic Usefulness of 18F-FAMT PET and L-Type Amino Acid Transporter 1 (LAT1) Expression in Oral Squamous Cell Carcinoma Eur J Nucl Med Mol Imag 2013 Oct;40(11):1692-700

7. Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. Lung Cancer. 2013 Oct;82(1):103-8.

8. Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, Oriuchi N, Kanai Y, Oyama T, Chikamatsu K. Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma. Pathol Oncol Res. 2013 Oct;19(4):649-56.

9. Imai H, Kaira K, Yoshino R, Sato K, Shimizu K, Kawashima O, Tanaka S, Mori M. Clinical Features of Patients with Invasive Thymoma: A retrospective analysis of 61 Cases. Surgical Practice 2013 in press.

10. Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene. 2013 Aug 22;32(34):4034-42.

11. Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N. Comparison of the time to response between radiotherapy and epidermal growth factor receptor tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutations. Anticancer Res. 2013 Aug;33(8):3279-84.

12. Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N. Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013 Jul;14(4):440-5.

13. Nakano S, Gibo J, Fukushima Y, Kaira K, Sunaga N, Taketomi-Takahashi A, Tsushima Y, Mori M. Perfusion Evaluation of Lung Cancer: Assessment Using Dual-input Perfusion Computed Tomography. J Thorac Imaging. 2013 Jul;28(4):253-62

14. Ohshima Y, Hanaoka H, Tominaga H, Kanai Y, Kaira K, Yamaguchi A, Nagamori S, Oriuchi N, Tsushima Y, Endo K, Ishioka NS. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography. Ann Nucl Med. 2013 May;27(4):314-24.

15. Watanabe A, Suzuki H, Yokobori T, Altan B, Kubo N, Araki K, Wada S, Mochida Y, Sasaki S, Kashiwabara K, Hosouchi Y, Kuwano H. Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis. Cancer Sci. 2013 Nov;104(11):1427-32.

16. Altan B, Yokobori T, Mochiki E, Ohno T, Ogata K, Ogawa A, Yanai M, Kobayashi T, Luvsandagva B, Asao T, Kuwano H. Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer. Carcinogenesis. 2013 Oct;34(10):2314-21.

2012

総説論文

1. Araki T, Yashima H, Shimizu K, Aomori T, Hashita T, Kaira K, Nakamura T, Yamamoto K. Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol. 2012;6:407-21.

2. Kaira K, Yamamoto N. Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer. Onkologie.

原著論文

1. Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N. The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy. Am J Clin Oncol. 2012 Dec 1.

2. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T, Takeyoshi I. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 2012 Aug 7;107(4):632-8.

3. Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, Kondo H, Nakajima T, Yamamoto N. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol. 2012 Feb 23. [Epub ahead of print]

4. Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012 May;48(8):1244-54.

5. Kaira K, Endo M, Shukuya T, Kenmotsu H, Naito T, Ono A, Tsuya A, Nakamua Y, Takahashi T, Murakami H, Kondo H, Nakajima T, Yamamoto N. ¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms? Neoplasma. 2012;59(3):257-63.

6. Kaira K, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Endo M, Kondo H, Nakajima T, Yamamoto N. Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol. 2012 Jun;20(3):223-32.

7. Kaira K, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Hayashi I, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. Eur J Radiol. 2012 Sep;81(9):2423-9. (Corresponding author) (IF=2.369)

8. Kaira K, Okumura T, Nakagawa K, Ohde Y, Takahashi T, Murakami H, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N. MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. Pathol Oncol Res. 2012 Apr;18(2):439-47.

9. Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Med Oncol. 2012 Sep;29(3):1663-72.

10. Kenmotsu H, Ohde Y, Shukuya T, Eida H, Akamatsu H, Ono A, Nakamura Y, Tsuya A, Kaira K, Naito T, Murakami H, Takahashi T, Maniwa T, Isaka M, Endo M, Kondo H, Yamamoto N. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan. Respir Investig. 2012 Dec;50(4):157-61.

11. Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Kakegawa S, Sugano M, Ibe T, Nagashima T, Kaira K, Sunaga N, Ohtaki Y, Atsumi J, Takeyoshi I. Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: gene expression associated with metastatic potential in human lung cancer. Oncol Rep. 2012 Nov;28(5):1727-35.

12. Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, Mawatari M, Matsumoto M, Sawamura M, Tsushima Y. ¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG. Ann Nucl Med. 2012 Dec;26(10):811-6.

13. Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, Kitashoji T, Ohgaki R, Tanaka H, Endou H, Endo K, Sakurai H, Kanai Y. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012 Aug;53(8):1253-61.

14. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012 Mar;32(3):1103-6.

15. Ono A, Naito T, Ito I, Watanabe R, Shukuya T, Kenmotsu H, Tsuya A, Nakamura Y, Murakami H, Kaira K, Takahashi T, Kameya T, Nakajima T, Endo M, Yamamoto N. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer. 2012 Jun;76(3):439-44.

16. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Kenmotsu H, Shukuya T, Kaira K, Koh Y, Endo M, Hasegawa S, Yamamoto N. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol. 2012 Mar;7(3):512-9.

17. Harada H, Seto T, Igawa S, Tsuya A, Wada M, Kaira K, Naito T, Hayakawa K, Nishimura T, Masuda N, Yamamoto N. Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1777-82. (IF=4.258)

18. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer. 2012 Apr 15;130(8):1733-44.

Copyright (C) 2013 - 2017 Department of MPO & OCD, Gunma University. All Rights Reserved.

▲ページの先頭に戻る